CollPlant Biotechnologies (CLGN) Free Cash Flow (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Free Cash Flow came in at -$2.9 million in Q4 2025, up 14.24% YoY from -$2.6 million in Q4 2024, and down 1.53% on a QoQ basis from -$2.9 million in Q3 2025.
CollPlant Biotechnologies (CLGN) Free Cash Flow (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Free Cash Flow data on file, last reported at -$2.9 million in Q4 2025.
- Quarterly Free Cash Flow rose 14.24% year-over-year to -$2.9 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 21.13% YoY) and the FY2025 annual result came in at -$9.4 million, up 31.0% from the prior year.
- Free Cash Flow eased to -$2.9 million in Q4 2025, from -$2.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $11.2 million in Q1 2021 to a low of -$12.4 million in Q4 2022.
- A 5-year average of -$2.1 million and a median of -$2.9 million in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 1152.42% — and 2023, when it soared 344.05%.
- Tracing CLGN's Free Cash Flow over 5 years: stood at -$992000.0 in 2021, then slumped by 1152.42% to -$12.4 million in 2022, then jumped by 82.97% to -$2.1 million in 2023, then sank by 60.92% to -$3.4 million in 2024, then climbed by 14.24% to -$2.9 million in 2025.
- The last three Free Cash Flow figures came in at -$2.9 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.92 Mn |
| Dec 31, 2025 | -2.92 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Sep 30, 2025 | -2.88 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Dec 31, 2024 | -3.41 Mn |
| Dec 31, 2024 | -3.41 Mn |
| Sep 30, 2024 | -3.31 Mn |
| Sep 30, 2024 | -3.31 Mn |
| Jun 30, 2024 | -3.73 Mn |
| Jun 30, 2024 | -3.73 Mn |
| Mar 31, 2024 | -3.17 Mn |
| Mar 31, 2024 | -3.17 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Sep 30, 2023 | 7.02 Mn |
| Sep 30, 2023 | 7.02 Mn |
| Jun 30, 2023 | -3.41 Mn |
| Jun 30, 2023 | -3.41 Mn |